These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10064000)

  • 1. Recombinant factor VIIa does not induce hypercoagulability in vitro.
    Gallistl S; Cvirn G; Muntean W
    Thromb Haemost; 1999 Feb; 81(2):245-9. PubMed ID: 10064000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution.
    Ovanesov MV; Panteleev MA; Sinauridze EI; Kireev DA; Plyushch OP; Kopylov KG; Lopatina EG; Saenko EL; Ataullakhanov FI
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):743-55. PubMed ID: 19002040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa.
    Eichinger S; Lubsczyk B; Kollars M; Traby L; Zwiauer K; Gleiss A; Quehenberger P; Kyrle PA
    Eur J Clin Invest; 2009 Aug; 39(8):707-13. PubMed ID: 19490067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of factor VIIa-dependent coagulation in hemophilia blood.
    Butenas S; Brummel KE; Branda RF; Paradis SG; Mann KG
    Blood; 2002 Feb; 99(3):923-30. PubMed ID: 11806995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects.
    Friederich PW; Levi M; Bauer KA; Vlasuk GP; Rote WE; Breederveld D; Keller T; Spataro M; Barzegar S; Büller HR
    Circulation; 2001 May; 103(21):2555-9. PubMed ID: 11382723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of factor VIII--bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: thrombin generation test in the presence of collagen-activated platelets.
    Sultan Y; Loyer F
    J Lab Clin Med; 1993 Mar; 121(3):444-52. PubMed ID: 8445292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
    Zollner S; Schuermann D; Raquet E; Mueller-Cohrs J; Weimer T; Pragst I; Dickneite G; Schulte S
    J Thromb Haemost; 2014 Feb; 12(2):220-8. PubMed ID: 24641308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
    Welsch DJ; Novotny WF; Wun TC
    Thromb Res; 1991 Oct; 64(2):213-22. PubMed ID: 1811340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
    Carr ME; Martin EJ; Kuhn JG; Seremetis SV
    Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
    Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
    Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates.
    Sadeghi N; Iacobelli M; Vaziri B; Kahn D; Hoppensteadt D; Guler N; Fareed J
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):211-220. PubMed ID: 27553841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.
    Hansson KM; Gustafsson D; Skärby T; Frison L; Berntorp E
    J Thromb Haemost; 2015 Jul; 13(7):1293-300. PubMed ID: 25944555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition.
    Li R; Panckeri KA; Fogarty PF; Diamond SL
    Haemophilia; 2015 Mar; 21(2):266-274. PubMed ID: 25311576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium.
    Mauser-Bunschoten EP; de Goede-Bolder A; Wielenga JJ; Levi M; Peerlinck K
    Neth J Med; 1998 Dec; 53(6):249-55. PubMed ID: 9883002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
    Campbell RA; Fischer TH; Wolberg AS
    Br J Haematol; 2007 Jul; 138(1):82-93. PubMed ID: 17555451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA.
    Parmar N; Berry LR; Paredes N; Chan AK
    Clin Lab; 2005; 51(3-4):157-66. PubMed ID: 15819171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
    Broze GJ; Higuchi DA
    Blood; 1996 Nov; 88(10):3815-23. PubMed ID: 8916945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
    Livnat T; Martinowitz U; Zivelin A; Seligsohn U
    Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.